Tundra Space

Tundra Space

Book DemoDirectoryLog InSign Up

Clinical Research Directory

Browse clinical research sites, groups, and studies.

SitesGroupsStudies
Back to Studies
RECRUITING
NCT06252870
PHASE2

Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Sponsor: Nantes University Hospital

View on ClinicalTrials.gov

Summary

Graft-versus-host disease (GVHD) is a major complication of allogeneic hematopoietic stem cell transplantation (allo-CSH). Recently, in the context of semi-identical (=haploidentical) HLA donors, but also of compatible HLA donors, the use of cyclophosphamide (CY) administered in high doses at early post-transplant (PT) (=PTCY) (Days +3 and +4 or +5) has shown excellent control of acute and chronic GVH, even enabling the discontinuation of other immunosuppressive drugs administered after allo-CSH (ciclosporin, mycophenolate mofetyl (MMF) or Cellcept). This step has already been taken in the context of allo-CSH with myeloablative conditioning (MAC), which is a minoritary conditioning in adults. However, in the context of allo-CSH with reduced-intensity conditioning (RIC), which predominates in adults, this strategy seems insufficient to prevent the risk of GVHD. The idea of reducing the use of immunosuppressants in the context of RIC/HLA-compatible transplants seems, however, still relevant, in order to reduce their adverse effects, improve patients' quality of life and enhance the reconstitution of the post-transplant immune system.

Official title: Randomized Phase 2 Study Testing Two Conditioning Regimen With a Single Prophylaxis of Graft-versus-host Disease by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

Key Details

Gender

All

Age Range

18 Years - 70 Years

Study Type

INTERVENTIONAL

Enrollment

82

Start Date

2024-07-18

Completion Date

2028-07-18

Last Updated

2026-01-26

Healthy Volunteers

No

Conditions

Graft Versus Host DiseaseHematologic Malignancy

Interventions

DRUG

Methotrexate

15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)

DRUG

Post-Transplant Cyclophosphamide

50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)

DRUG

Fludarabine

Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)

DRUG

Cycophosphamide

Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)

DRUG

Anti-Thymoglobulin

Conditioning regimen: 2.5 mg/kg intravenous on Day-2 before graft (=Day0)

RADIATION

total body irradiation

2 grays on Day-1 before graft (=Day0)

OTHER

hematopoietic stem cells

High dose of hematopoietic stem cells derived from peripheral blood on transplantation day (=Day0 graft)

OTHER

Graft nuclear cells

Graft nuclear cells CD3+ cells if needed after transplantation

OTHER

Donor Lymphocytes Injection

DLI with CD3+ if relapse after transplantation or in prevention of relapse

DRUG

Clofarabine

Conditioning regimen: 30 mg/m² Intravenous 5 days from Day-6 to Day-2 (Day-6/Day-5-/Day-4/Day-3/Day-2 before graft (=Day0)

DRUG

Thiotepa

Conditioning regimen: 5 mg/kg Intravenous at Day-6 before graft (=Day0)

DRUG

Busulfan

Conditioning regimen: 3.2 mg/kg Intravenous 2 days at Day-2 and Day-1 before graft (=Day0)

DRUG

Fludarabine

Conditioning regimen: 40 mg/m² intravenous 4 days on Day-5/Day-4/Day-3/Day-2 before graft (=Day0)

Locations (3)

CHU Angers

Angers, France

CHU Brest

Brest, France

CHU Nantes

Nantes, France